BioNTech SE Enters Purchase Agreement with CureVac N.V.
Ticker: BNTX · Form: 6-K · Filed: 2025-06-12T00:00:00.000Z
Sentiment: neutral
Topics: agreement, partnership, biotech
TL;DR
BioNTech inks deal with CureVac on June 12, 2025. Details in joint press release.
AI Summary
On June 12, 2025, BioNTech SE announced a Purchase Agreement with CureVac N.V., also dated June 12, 2025. This agreement was detailed in a joint press release issued by both companies.
Why It Matters
This agreement signifies a strategic partnership or transaction between two key players in the biotechnology sector, potentially impacting their research, development, or manufacturing capabilities.
Risk Assessment
Risk Level: low — The filing is a routine 6-K report announcing a standard business agreement, with no immediate financial or operational risks apparent.
Key Players & Entities
- BioNTech SE (company) — Registrant and party to the agreement
- CureVac N.V. (company) — Party to the agreement
- June 12, 2025 (date) — Date of the Purchase Agreement and press release
FAQ
What is the nature of the Purchase Agreement between BioNTech SE and CureVac N.V.?
The filing does not specify the exact nature of the Purchase Agreement, only that it was entered into on June 12, 2025, and announced via a joint press release.
When was the Purchase Agreement between BioNTech SE and CureVac N.V. finalized?
The Purchase Agreement was dated as of June 12, 2025.
What form is this SEC filing?
This is a Form 6-K report.
What is BioNTech SE's primary business?
BioNTech SE's Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Where is BioNTech SE headquartered?
BioNTech SE is headquartered in Mainz, Germany.
From the Filing
0001193125-25-139910.txt : 20250612 0001193125-25-139910.hdr.sgml : 20250612 20250612161907 ACCESSION NUMBER: 0001193125-25-139910 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20250612 FILED AS OF DATE: 20250612 DATE AS OF CHANGE: 20250612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251042831 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 d40967d6k.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒    Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On June 12, 2025, BioNTech SE and CureVac N.V. issued a joint press release announcing their entry into a Purchase Agreement, dated as of June 12, 2025. A copy of the joint press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Prof. Dr. Ugur Sahin    By: /s/ Dr. Sierk Poetting Name: Prof. Dr. Ugur Sahin Name: Dr. Sierk Poetting Title: Chief Executive Officer Title: Chief Operating Officer Date: June 12, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer EX-99.1 2 d40967dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer • Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy • Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing • Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to CureVac’s three-month volume weighted average price of approx. $3.53 as of June 11, 2025 • All-stock acquisition has potential to create long-term value for both companies’ shareholders given their complementary capabilities, focus on mRNA innovation, and shared vision • Transaction is supported by CureVac’s major shareholder dievini Hopp BioTech holding GmbH & Co. KG and certain of its affiliates and expected to close in 2025 MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive